upcyte head welcome

upcyte technologies – expanded primary cells

…. have you ever been concerned that your cell based assay is not relevant enough to provide you with satisfying results?
…. have you ever been forced to reduce the number of data points simply by the limitation of appropriate assay cells?

The possibility to scale up mammalian cells economically and the loss of cell-type specific properties have long been two sides of a coin. A downside which had to be accepted when assay reproducibility and throughput were obligatory needs.
upcyte technologies has managed to split this coin and is providing a solution which combines large scale cell expansion with physiological relevance. By using the proprietary upcyte® protocol non-dividing primary cells are pushed back into proliferation without altering their most relevant tissue-specific characteristics.
upcyte technologies can generate homogenous cell batches of up to 10 billion physiologically relevant cells from cell types which are otherwise limited. upcyte technologies provides assay-ready cells from various upcyted® human healthy or diseased tissues along with optimized medium formulations to make cell-based screening even more relevant and your early ADME-Tox screen more predictive.

Eurotox

Seville (Spain) on Sept 4-7, 2016

ISSX Workshop

Boston (USA) on Oct 27-28, 2016

American College of Toxicology

Baltimore (USA) on Nov 6-9, 2016

Agreement with INDIGO Biosciences! Read more here.

indigo

Latest publication from the University of Valencia in Tox Sciences 

Tolosa et al.  link

upcyte technologies GmbH

Osterfeldstraße 12-14
22529 Hamburg
Germany

Tel: +49 (0) 40/63730308

info@upcyte.com

© 2016 by upcyte technologies GmbH // Osterfeldstraße 12-14 // 22529 Hamburg // Germany